Ivonescimab plus chemo before and after surgery for stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding the drug ivonescimab to standard chemotherapy, given before and after surgery, helps shrink tumors and lower the chance of the cancer coming back in people with advanced stomach cancer that can be removed with surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have stomach or gastroesophageal junction (food pipe-stomach connection) cancer that has spread into nearby tissues but not to other parts of the body.
- You have not had any prior treatment for this cancer.
- You have not had certain genetic changes in the tumor called dMMR or MSI-H.
- You do not have uncontrolled high blood pressure, bleeding tumors, or recent blood clots or digestive perforations.
- Your general health is good enough for surgery and chemotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four drugs given before surgery for stomach cancer that can be removed but is considered borderline resectable. The goal is to shrink the tumor to make surgery more successful and potentially improve outcomes.
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a new combination of an immunotherapy drug (cadonilimab) with chemotherapy before surgery for stomach cancer. The goal is to see if this approach shrinks tumors more effectively and improves outcomes.
This trial tests a combination of three drugs (Disitamab Vedotin, Toripalimab, and XELOX) given before and after surgery for gastric or gastroesophageal junction cancer. The goal is to see if this treatment helps shrink the tumor and prevent it from coming back.
This trial compares two types of chemotherapy with or without an immunotherapy drug (tislelizumab) for advanced stomach or gastroesophageal junction cancer. It aims to see which combination works better and has fewer side effects.
This trial tests a combination of three drugs (envollizumab, fruquintinib, and chemotherapy) given before surgery, to see if it can shrink stomach cancer enough to make it removable. It compares this combination to chemotherapy alone.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.